Why Biohaven Stock Was Rocking the Market This Week
Key PointsIts partner is South Korean peer SK Biopharmaceuticals.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
More in Finance & Markets
Deepexi Technology reports quarterly profitability and revenue growth
Enterprise software provider Deepexi Technology achieved positive quarterly net profit and revenue growth following increased commercial deployment of its proprietary agentic artificial intelligence…
- Deepexi Technology reports 115% revenue growth YoY in H1 2026
- AI revenue surges 209%, accounting for 79.6% of total revenue
- Quarterly net profit reaches RMB 30.1 million, achieving profitability
(2nd LD) Seoul stocks snap 3-day rise on tech slump
SEOUL, Aug. 28 (Yonhap) -- Seoul stocks closed sharply down Friday to snap their...
Samsung Biologics rights offering highlights future growth, but stock price drops
Samsung Biologics will issue new shares worth 3 trillion won ($2.17 billion) to finance its planned acquisition of a Swiss-headquartered contract drug manufacturer and the expansion of its…
Asia FX: Central banks act as risk managers – MUFG
MUFG’s Michael Wan reviews recent decisions by Bank of Korea (BoK), Bangko Sentral ng Pilipinas (BSP) and Bank of Japan (BoJ), stressing a shared risk-management approach under uncertainty.
IT stocks power markets; Sensex up 165 points at noon as investors await Warsh speech
TCS leads Nifty 50 gainers, rising 3.81% to ₹2,334 against a previous close of ₹2,248.40
FTSE Russell to reclassify Nigeria into Frontier Market status
Commenting on the development, Temi Popoola, Group Managing Director/Chief Executive Officer, NGX Group, said, “This is an important moment for Nigeria’s capital market." The post FTSE Russell to…